Back to All Resources

BlueWind Medical Appoints Dan Lemaitre as Chief Executive Officer


BlueWind Medical, the developer of the RENOVA iStimâ„¢, an innovative leadless miniature neurostimulation platform initially being developed for the treatment of overactive bladder (OAB), has announced the appointment of Daniel T. Lemaitre as Chief Executive Officer (CEO), effective from January 1st, 2020. Mr. Lemaitre has previously served as the Chairman of the Board of BlueWind Medical since November 2018. He is also a board member of Globus Medical and serves as the Chairman of Endologix. Mr. Lemaitre was the CEO of CoreValve, a pioneer in the transcatheter heart valve market, which was acquired by Medtronic for $800 Million. Prior to that, he was the Senior Vice President of Strategy and Business Development at Medtronic. Earlier in his career, he was a top-ranked medical device analyst, initially at Cowen & Company and later at Merrill Lynch.

“Ilan Neugarten, Chairman of the board of Rainbow Medical, BlueWind Medical’s largest investor, said, “Dan is assuming the role of CEO at a critical time for the company and for the OAB market. With his tremendous experience, Dan will help transform BlueWind from a technology stage company to a leading player in the neuromodulation market.”

“BlueWind has the potential to revolutionize the treatment of OAB, which impairs the quality of life of millions of patients in the US and around the world,” said Lemaitre. “Our RENOVA device is easy to implant, potentially devoid of severe complications, and is in a form factor that works for physicians and patients alike. With our technology and a spectacular team, we expect to help many patients with our technology that was not adequately treated with conservative or more invasive technologies before.”

“We are excited about the potential of our technology and are looking forward to a successful journey with Dan’s leadership as we embark on our pivotal study at sites in Europe and the United States,” said Guri Oron, who served as CEO for the previous six years and will assume the role of President and General Manager.”

About BlueWind Medical:
BlueWind Medical ( was founded in 2010 by Rainbow Medical. The company is developing a platform technology of miniature, wireless neurostimulators that can be injected or implanted in a minimally invasive procedure to treat multiple indications. The RENOVA system has a CE Mark and is an investigational device that is not cleared for marketing in the United States.

Roy Katz